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Abstract
Protein aggregation underlies a wide range of human disorders. The polypeptides involved in these pathologies might be
intrinsically unstructured or display a defined 3D-structure. Little is known about how globular proteins aggregate into toxic
assemblies under physiological conditions, where they display an initially folded conformation. Protein aggregation is,
however, always initiated by the establishment of anomalous protein-protein interactions. Therefore, in the present work,
we have explored the extent to which protein interaction surfaces and aggregation-prone regions overlap in globular
proteins associated with conformational diseases. Computational analysis of the native complexes formed by these proteins
shows that aggregation-prone regions do frequently overlap with protein interfaces. The spatial coincidence of interaction
sites and aggregating regions suggests that the formation of functional complexes and the aggregation of their individual
subunits might compete in the cell. Accordingly, single mutations affecting complex interface or stability usually result in
the formation of toxic aggregates. It is suggested that the stabilization of existing interfaces in multimeric proteins or the
formation of new complexes in monomeric polypeptides might become effective strategies to prevent disease-linked
aggregation of globular proteins.
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Introduction
The formation of insoluble amyloid protein deposits in tissues is
related to the development of more than 40 different human
diseases, many of which are debilitating and often fatal. The
polypeptides responsible for these disorders are not related in
terms of sequence or conformation [1–6]. Some of these proteins
and peptides are mostly unstructured. Examples include amylin,
amyloid-b-protein and a-synuclein. In contrast, many other
amyloidogenic proteins are globular in their native state, implying
that they have a properly packed and cooperatively sustained
structure under physiological conditions. This group includes ß-2-
microglobulin, transthyretin, lysozyme, superoxide dismutase 1
and immunoglobulins. As a general trend, evolution has endorsed
globular proteins with solubility in their biological environments
[7]. However, it has been shown that, in vitro, under conditions
where they become totally or partially unfolded, both these
pathogenic proteins [8–11] and many globular polypeptides not
related to disease [12–15] readily convert into aggregates and
ultimately into highly structured amyloid fibrils. This self-assembly
process is triggered by the destabilization and opening of the
native structure, which exposes previously protected aggregation-
prone regions that can nucleate the aggregation reaction and
participate in forming the b-core of the mature fibril through
specific intermolecular interactions [16–18]. Such amyloidogenic
sequence stretches have been described in most of the polypeptides
underlying neurodegenerative and systemic amyloidogenic disor-
ders. The main intrinsic protein properties that promote the
assembly of such sequences into fibrils have been recently defined
[19], and several algorithms that predict amyloidogenic sequences
with good accuracy are already available [3,20,21].
Although the study of protein aggregation from non-native
states has provided a wealth of data on the physico-chemical
determinants of amyloid formation, little is known about how
globular proteins aggregate from their initially folded and soluble
conformations under physiological conditions, where extensive
unfolding is not expected to occur [22]. Deciphering this issue is
important because the deposition of globular polypeptides is linked
to devastating disorders, and there is an urgent need for
therapeutic intervention.
Protein aggregation can be seen as an anomalous type of
protein-protein interaction. In functional interactions, binding
partners come together in a stable and precise orientation in
seconds [23]. This efficiency relies on the structural features of the
interacting surfaces. Perhaps the most significant characteristic of a
functional protein-protein interface is the presence of small high-
affinity regions within the interface, with a reduced number of
residues accounting for most of the binding energy [24–26].
Several computational approaches have been shown to forecast
such regions with high accuracy [27–34]. Statistical analysis of the
structures of protein-protein interfaces has revealed that trypto-
phan, phenylalanine, and methionine and to a lesser extent
leucine, valine, and tyrosine are preferentially conserved at
interaction sites [35]. The same residues have been shown to be
conserved in the aggregation-prone sequences of the human
proteome [36]. This suggests an intriguing possibility: that
amyloidogenic regions and interacting surfaces might overlap in
globular proteins. Several of the folded proteins linked to amyloid
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diseases display quaternary structure or are bound to other
proteins in their physiological context. If these interactions
specifically cover amyloidogenic regions, they could play a role
in protecting native-state proteins from aggregation. Alternatively,
incorrect docking of interfaces might facilitate the assembly of
overlapping amyloidogenic regions and therefore the formation of
toxic protein aggregates of globular proteins. In the present work,
we have used available computational approaches to predict
aggregation-prone sequences and interacting residues in order to
assess the extent to which these regions coincide in pathogenic and
non-pathogenic proteins.
Results/Discussion
Prediction of Aggregation-Prone Regions and Protein-
Protein Interaction Sites
The prediction of regions responsible for aggregation based on
the primary sequence of a protein has been tackled by several
methods, from simple considerations of the properties of amino
acids to complex molecular dynamics calculations [37–44].
Overall, most of these methods predict with reasonable precision
the regions of proteins in the cross-ß core of amyloid fibrils. This
accuracy allows the proposal that the aggregation propensity of a
polypeptide chain is ultimately dictated by the sequence [45]. Here
we have used four different algorithms in parallel to provide a
consensus prediction of the amyloidogenic regions in globular
proteins linked to deposition diseases (see Methods). We chose the
algorithms implemented by Fernandez-Escamilla et al. (TANGO)
[38], Conchillo-Sole et al. (AGGRESCAN) [40], Galzitskaya et al.
[41], and Zhang et al. [43]. All of them use the primary sequence
as input and assume that the detected regions need to be at least
partially exposed to solvent in order to nucleate the aggregation
reaction.
Identification of binding sites in polypeptides is a direct
computational approach to deciphering biological and biochem-
ical function. Although sequence-based approaches to identifying
protein interfaces exist, their results are often unsatisfactory. Here,
we have used three different structure-based methods whose
algorithms are publicly available as web servers to produce a
consensus prediction of the interaction interfaces in the globular
proteins under consideration (see Methods). These structure-based
methods were developed by Fernandez-Recio et al. (ODA) [32],
Murakami and Jones (SHARP2) [31], and Negi et al. (InterProSurf)
[33]. Although they are based on different principles and
implement diverse computational strategies, all of them use the
unbound three-dimensional structure of a globular protein as
input.
Two levels of prediction were considered: i) residues predicted
or shown to be both in aggregation-prone regions and at interfaces
and ii) residues in aggregation-prone sequences that are close in
space to the interaction surface (below 3 A˚). The interaction
predictions were compared with the experimentally determined
contacts in the quaternary structure of the proteins or in
complexes of the studied proteins with other polypeptides. The
regions predicted to have high aggregation propensity were
compared with fragments of the analyzed proteins shown
experimentally to form amyloid aggregates or to be located in
the core of the mature fibrils formed by these polypeptides. We
have defined a parameter called Interface Proximity Index (IPI) to
evaluate the degree to which an aggregation-prone region is closer
to a given interface than to the rest of the protein surface (see
Methods and Figure 1).
Human ß2-Microglobulin
Amyloidosis related to b2-Microglobulin (b2-m) is a common
and serious complication in patients on long-term hemodialysis
[46]. Two aggregation-prone regions encompassing residues 22–
31 and 60–70 were predicted for human b2-m (Figure 2). These
regions neatly coincide with two secondary structure elements in
b2-m: b-strand 2, formed by residues 21–31, and b-strand 6,
formed by residues 61–71. Interestingly, most of the residues in
these two regions appear to be solvent accessible (Table 1). In
agreement with the prediction, the fragments 21–31 and 21–41 of
b2-m self-assemble into fibrillar structures [47]. Also, a peptide
corresponding to residues 59–79 and its shorter version 59–71
both form amyloid fibrils [48].
A main interaction cluster is predicted for human b2-m
(Figure 2A). It involves Y26 and G29 in b-strand 2, residues
H31-S33 in the loop connecting b-strands 2 and 3, residues D53-
W60 in b-strand 5 and the adjacent loop, and finally, residues F62
and L63 in b-strand 6. Overall, 62% of the residues in regions with
high aggregation propensity are less than 3 A˚ from predicted ‘‘hot
spots’’ of interaction (Table 1), and 25% overlap with them.
Specifically, residues at positions 26, 29, 31, 60, 62, and 63 are
predicted to be important both for binding and for aggregation.
Class I major-histocompatibility-complex (MHC) molecules
(HLA molecules in humans) are ternary complexes of b2-m, an
MHC heavy chain, and a bound peptide [49]. The crystal
structures of several of these complexes have been solved,
providing a benchmark to evaluate the accuracy of the predicted
interface. In HLA-A-class molecules, the interface of b2-m and the
HLA heavy chain is well conserved [50] and typically comprises
16 b2-m residues: K6, Q8, 10Y, 11S, 12R, N24, Y26, H31, D53,
S55, F56, W60, F62, Y63, D98 and M99. This includes 8 of the 15
interacting residues predicted for b2-m. Residues 24, 26, and 31
map to the first aggregation-prone region of b2-m, and residues
60, 62, and 63 map to the second one. Taking as an example the
structure of one such HLA-A complex (PDB ID: 1DUZ) [51],
85% of the residues in b2-m aggregating regions are less than 3 A˚
from the interface in the complex (Table 1 and Figures 2B, 2D and
2E). The IPI values confirm that these regions are preferentially
located close to the interface of the complex (Table 1 and
Figure 1A).
Author Summary
The aggregation of proteins in tissues is associated with
the pathogenesis of more than 40 human diseases. The
polypeptides underlying disorders such as Alzheimer’s and
Parkinson’s are devoid of any regular structure, whereas
the polypeptides causing familial amyotrophic lateral
sclerosis or nonneuropathic systemic amyloidosis corre-
spond to globular proteins. Little is known about the
mechanism by which globular proteins under physiolog-
ical conditions aggregate from their initially folded and
soluble conformations. Interestingly, several of these
pathogenic proteins display quaternary structure or are
bound to other proteins in their physiological context. In
the present work, we show that protein-protein interaction
surfaces and regions with high aggregation propensity
significantly overlap in these polypeptides. This suggests
that the formation of native complexes and self-aggrega-
tion reactions probably compete in the cell, explaining
why point mutations affecting the interface or the stability
of the protein complex lead in many cases to the
formation of toxic aggregates. This study proposes general
strategies to fight against diseases associated with the
deposition of globular polypeptides.
Globular Proteins Aggregation
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Inside the cell, b2-m associates with the non-classical HLA class
I molecule human hemochromatosis protein (HFE) [52]. Hered-
itary hemochromatosis is a genetic disorder characterized by
defects in iron metabolism and associated with mutations in the
HFE gene [53]. Some of these mutations prevent the binding of
HFE to b2-m. There are 18 b2-m residues at the HFE/b2-m
complex interface, according to its crystal structure (PDB ID:
1A6Z) [54] : I1, Q8, 10Y, 11S, 12R, N24, Y26, H31, D53, L54,
S55, F56, W60, Y63, F62, L65, D98, and M99, including 9 of the
15 predicted interaction sites. Residues 24, 26, and 31 correspond
to the first aggregation-prone region of b2-m and residues 60, 63,
62, and 65 to the second. Another significant feature of this
complex is that 76% of the residues in regions with high
aggregation potential are close to the interface with b2-m
(Table 1 and Figure 2C). Therefore, the docking of the HLA
heavy chain and HFE molecules on top of b2-m covers most of the
residues in aggregation-prone regions because they are close to the
interaction sites, as illustrated by their high IPIs (Table 1,
Figure 1A and Figures 2F, 2G).
Aggregation of b2-m under physiological conditions is thought
to be initiated by a cis-trans prolyl isomerization of the H31-P32
peptide bond [22]. The transition promotes repositioning of the
hydrophobic side chains of F30, L54, F56, W60, F62, and Y63 as
shown in the structures of the P32A and P32G mutants [55,56].
Interestingly enough, all of these residues map in an aggregation-
prone segment and/or at the interface. Although speculative, it is
tempting to propose that conditions that promote the dissociation
of b2-m complexes with the above proteins or related ones may
uncover this region and facilitate its fluctuation towards amyloi-
dogenic conformations. In fact, in vivo, b2-m is continuously shed
from the HLA molecules in the cell surface into the serum and
transported to the kidneys where it is eliminated. Renal failure
increases the levels of circulating b2-m more than 50-fold and
promotes its self-assembly and conversion into amyloid fibrils [57].
Consequently, dissociation of b2-m from the class I HLA complex
effectively constitutes a critical initial step in its aggregation into
amyloid fibrils.
Because the b2-m regions likely to be involved in aggregation
are already located in preformed b-strands, local fluctuations may
allow anomalous intermolecular interactions between these
preformed elements, leading to the formation of an aggregated
b-sheet structure without extensive unfolding. In this context, the
formation of b2-m complexes both inside the cell and on the cell
surface might play a protective role against b2-m aggregation,
either by reducing conformational fluctuations or by preventing
the exposure of dangerous amyloidogenic regions, or both.
Human Transthyretin
Transthyretin (TTR) constitutes the fibrillar protein found in
familial amyloidotic polyneuropathy (FAP), familial amyloidotic
cardiomyopathy, and central nervous system amyloidosis. Around
100 different TTR mutations have been reported, many of which
Figure 1. Interface Proximity Index (IPI) of aggregation-prone regions in human globular amyloidogenic proteins. Aggregation-prone
regions are coloured according to their IPI values (see the scale). A) b2-microglobulin, B) transthyretin, C) immunoglobulin G heavy chain, D) SOD1
and E) immunoglobulin light chain variable domain.
doi:10.1371/journal.pcbi.1000476.g001
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are amyloidogenic [58]. Native TTR is a homotetramer. Five
aggregation-prone regions are predicted for the TTR monomer.
They encompass residues 11–19, 26–34, 92–96, 105–112, and
115–121. In this case, the aggregation-prone sequences appear to
coincide precisely with preformed b-sheet structures: A b-strand
(11–19), B b-strand (26–36), F b-strand (91–97), G b-strand (105–
112), and H b-strand (115–121). In concordance with the
prediction, peptides 10–20 and 105–115, which map in the first
and fourth aggregation-prone regions, have been shown to
assemble into amyloid fibrils [59,60].
A single interaction patch is predicted for the TTR monomer
(Figure 3A). It involves 19 residues located in the A b-strand (L17,
A19), in the loop between the A and B b-strands (V20–S23), in the
a-helix (L82), in the loop between the helix and the F b-strand
(S85-F87), in the F b-strand (E92), in the G and H b-strands, and
in the loop between the G and H b-strands (L110, S112-T118).
TTR is a dimer of dimers. In the dimers formed by the A and B or
the C and D chains, the predicted clusters are contiguous, forming
a large and continuous interaction patch. Of the residues in
aggregation-prone regions in TTR, 41% are within 3 A˚ of
predicted interaction sites (Table 1). With the exception of the I26-
R34 fragment, all the regions with high aggregation propensity are
located close to the predicted interface, and 30% of the residues in
these segments overlap with predicted interaction sites. Residues
17, 19, 92, 110, 112, and the stretch 115–118 are predicted to be
important both for aggregation and interaction events.
The crystal structure of the TTR tetramer (PDB ID: 1TTA)
[61] reveals that the real interfaces between the four individual
TTR chains involve residues L17, A19-S23, F87-E89, E92, V94-
T96, Y105, L110, and S112-V122. In good agreement with the
prediction, the interfaces include 16 of the 19 predicted interacting
residues. Residues 17 and 19 map to the first aggregation-prone
region, residues 92 and 94–96 to the third one, and residues 110
and 112–122 to the fourth and fifth stretches. Significantly, if we
exclude the I26-R34 region (IPI,0), 90% of the residues in
aggregating regions are close to the two interfaces of the TTR
tetramer as confirmed by their overall high IPIs (Table 1,
Figure 1B and Figures 3B, 3C). Accordingly, although these
regions are mostly accessible to solvent in the monomer, they
become protected in the native quaternary structure of TTR by
the interaction of the TTR subunits (Figure 3D).
Dissociation of the TTR tetramer has been reported as a
prerequisite for amyloidosis. The tetrameric structure dissociates
into AB and CD dimers, but they are unstable in the absence of
additional quaternary interactions, explaining why TTR exists in a
primarily tetramer-monomer equilibrium [62]. The crystal
structures of more than 10 FAP-related variants have been solved,
showing that the mutants are essentially identical in tertiary and
quaternary structure to the wild-type protein, precluding the
presence of preformed conformational defects in the amyloido-
genic mutants [63]. However, FAP-associated mutants are
destabilized even when tetrameric. This destabilization favors
tetramer dissociation to the amyloidogenic monomeric intermedi-
ate, exposing previously hidden, preformed, aggregation-prone b-
strands. In this context, the overlap of interaction and aggregation
surfaces in the AB and CD dimers appears to be an effective way
Figure 2. Aggregation and interaction regions in human ß2-microglobulin. In all panels, b2-microglobulin aggregation-prone residues at
less and more than 3 A˚ from interaction sites are shown in red and green, respectively. Interface residues not included in aggregation-prone regions
are shown in dark blue. Rest of residues are shown in light blue. A) The predicted interaction surface for monomeric b2-microglobulin is used for
calculation. B) The interface between b2-microglobulin and HLA heavy chain is used for calculation (PDB ID:1DUZ). C) The interface between b2-
microglobulin and HFE is used for calculation (PDB ID:1A6Z). D and E) Front (same orientation that in B) and back view of the b2-microglobulin/HLA
heavy chain complex. F and G) Front (same orientation that in C) and back view of the b2-microglobulin/HFE complex.
doi:10.1371/journal.pcbi.1000476.g002
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Table 1. Comparison of aggregation predictions and experimental available data for human globular proteins and proximity of
aggregation-prone regions to predicted and real interfaces.
Predicted Aggregation
segments Fibril formers
% residues close to
predicted Interface1
% residues close to
real interface2 IPI
% solvent accessible
residues
ß2-Microglobulin (HLA)
22–31 21–31 70 (20) 100 (18) 0.88 65
21–41
60–70 59–79 54 (24) 73 (30) 0.58 100
59–71
ß2-Microglobulin (HFE)
22–31 21–31 70 (20) 70 (12) 0.83 65
21–41
60–70 59–79 54 (24) 81 (31) 0.62 100
59–71
Transthyretin
11–19 10–20 44 (22) 77 (36) 0.46 66
26–34 - 0 (53) 0 (68) ,0 66
92–96 - 40 (42) 100 (0) 1 100
105–112 105–115 62 (30) 100 (40) 0.6 100
115–121 - 62 (32) 100 (0) 1 100
SOD1
4–8 - 0 (13) 100 (3) 0.97 66
100–106 - 43 (12) 0 (19) ,0 66
111–120 - 70 (18) 50 (14) 0.72 100
146–153 - 87 (21) 87 (2) 0.97 100
Lysozyme
25–33 - 33 0 (25) ,0 44
57–66 - 90 40 (32) 0.20 60
76–84 26–123 56 56 (25) 0.55 88
108–114 - 86 0 (46) ,0 100
Immunoglobulin (LC)
19–23 - - 0 (38) ,0 71
31–38 - - 89 (24) 0.71 75
46–51 - - 50 (30) 0.4 71
71–78 - - 0 (43) ,0 62
84–89 - - 83 (18) 0.78 66
Immunoglobulin (HC)
29–38 - - 50 (20) 0.60 80
45–52 - - 75 (25) 0.67 82
87–93 - - 57 (24) 0.58 57
100–106 - - 100 (16) 0.84 100
275–281 - - 0 (31) ,0 71
289–299 - - 0 (52) ,0 100
322–331 - - 0 (37) ,0 80
390–396 - - 63 (13) 0.79 57
435–442 - - 100 (16) 0.84 75
1Percentage of residues in the aggregation-prone region at less than 3 A˚ from a protein predicted interaction residue.
2Percentage of residues in the aggregation-prone region at less than 3 A˚ from a residue located at the interface of the following complexes: b2-microglubulin in
complex with HLA heavy chain [1DUZ] and with HFE [1A6Z]. Native tetrameric structure of transthyretin (PDB code 1TTA). Dimeric structure of SOD1 (PDB code 2C9V).
Lysozyme in complex with a camelid antibody (PDB code 1OP9). Dimeric structure of Immunoglobulin LC variable domain (PDB code 2Q20). HCs and LCs of a IgG1
human immunoglobulin (PDB code 1HZH).
1,2In brackets the percentage of residues in the aggregation-prone region close to a random surface of the same size than the considered interface.
doi:10.1371/journal.pcbi.1000476.t001
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to prevent TTR amyloidogenesis in physiological conditions. The
success of this strategy is best exemplified by the behavior of the
T119M TTR mutant. The presence of the T119M allele alleviates
the effect of the aggressive V30M amyloidogenic mutation in
patients carrying these two variants. It has been shown that
heterotetramers that incorporate T119M subunits are more stable,
dissociate at lower rates, and accordingly are less amyloidogenic
[64].
Human Copper-Zinc Superoxide Dismutase
Familial amyotrophic lateral sclerosis (fALS) is characterized by
the presence of Copper-Zinc Superoxide Dismutase (SOD1)
inclusions in spinal cords [65]. Native SOD1 is a homodimer.
The SOD1 monomer displays four regions with high aggregation
potential. They encompass residues 4–8 in ß-strand 1, 100–106
and 111–120 in ß-strands 6 and 7 and the loop connecting them,
and residues 146–153 in ß-strand 8.
A total of 14 residues are predicted to be at the interface of the
SOD1 monomer (Figure 4A). They correspond to E21, W32,
G33, S105, S107, G108, H110, C111, I113-R115, G147, V148,
and I151. Of the residues in aggregation-prone regions in SOD1,
61% are less than 3 A˚ from predicted interaction sites (Table 1),
and 25% of them overlap the predicted interaction sites. In
particular, residues 105, 111, 113, 114, 115, 147, 148, and 151 are
predicted to be involved in both binding and aggregation.
According to the crystal structure of the SOD1 dimer (PDB ID:
2C9V) [66], the real interface between the two SOD1 subunits
involves residues V5, V7, F50-T54, I113-R115, V148, and G150-
Q153 (Figure 4B). Therefore, the interaction prediction is poor for
the N-terminal part of SOD-1 but accurate for residues in the C-
terminal region. Residues V5 and V7 are part of the first
aggregation-prone region, S105 part of the third one, I113-R115
part of the fourth stretch, and V148 and G150-Q153 part of the
last one. All the residues in the first and last aggregation-prone
segments as well as residues C111-T116 are close to the dimer
interface (Table 1). Accordingly, except for the 100–106 stretch
(IPI,0), all the regions with high aggregation propensity in SOD
display high IPIs (Table 1 and Figure 1D). Three out of the four
cysteine residues in each SOD1 monomer (6, 111, and 146) are in
those sequence stretches. C6 and C111 are present in the form of
free cysteines whereas C146 forms a disulfide bond with C57. All
of these regions are accessible to solvent in the monomeric form
but become partially or totally protected upon dimer association
(Figure 4C and 4D).
FALS has been shown to be associated with more than 100
different SOD1 mutations, which are scattered throughout the
Figure 3. Aggregation and interaction regions in human transthyretin. In all panels, transthyretin (TTR) aggregation-prone residues at less
and more than 3 A˚ from interaction sites are shown in red and green, respectively. Interface residues not included in aggregation-prone regions are
shown in dark blue. Rest of residues are shown in light blue. A) The predicted interaction surface of a TTR monomer is used for calculation. B) The
interface in the native tetrameric structure of TTR is used for calculation (PDB ID:1TTA). C) Dimer of TTR. D) TTR native tetrameric structure. The first
dimer is twisted 90u relative to C, the second one is shown in yellow.
doi:10.1371/journal.pcbi.1000476.g003
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three-dimensional structure [67]. Among them, the A4V mutation
has received special attention because it results in a rapidly
progressing form of fALS [68]. Animal models suggest that the
pathogenicity of the A4V SOD1 arises from an increased propensity
to aggregate, forming amyloid fibrils or pores [69]. A4 is near the
dimer interface and maps in the first aggregation-prone region.
Hasnain and co-workers solved the crystal structures of dimeric
forms of A4V and another FALS mutant, I113T [70]. I113 is also at
the interface, in the third aggregation-prone region. Both variants
display the same monomer fold and active-site geometry as WT, but
their interfaces are destabilized. Ray and Lansbury have shown that
a covalent link between the two A4V SOD1 subunits abolishes
aggregation, suggesting that the monomer is an obligate interme-
diate along the aggregation pathway [71]. Other studies also
support the idea that monomerization leads directly to aggregation
and fibrilization [72]. However, other lines of evidence suggest that
the cytotoxic properties of SOD1 are triggered by an incorrect
connection of its cysteine residues. In support of this view, the
toxicity of recombinant SOD1 in cultured cells is lost upon
mutational removal of C6 and C111 [11], and nucleation of the
aggregation reaction requires the presence of cysteine thiolates at
both positions 57 and 146 [72]. In any case, it appears that the
interface plays a protective role against aggregation in SOD1, by
preventing the direct assembly of pre-formed and exposed
aggregation-prone regions in the monomer, by stabilizing the
monomer against conformational fluctuations that might expose
amyloidogenic sequences, or by preventing the exposure and
reshuffling of cysteine residues. Based on these observations, it has
been proposed that the stabilization of the SOD1 dimer interface
could become an effective approach to fight against fALS [71].
Human Immunoglobulins
The light chains (LCs) of immunoglobulins have been
implicated in the pathogenesis of amyloidosis in patients with
monoclonal B-cell proliferative disorders (AL amyloidosis) [73].
When immunoglobulin molecules are secreted, two heavy chains
(HCs) usually pair with two LCs to create a heterotetramer.
Occasionally, free LCs are secreted, and these LCs can form
homodimers. LC dimers can be innocuous, but they can also
aggregate into pathogenic species. We have analyzed the
aggregation propensity and interfaces of a non-pathogenic LC
dimer (PDB ID: 2Q20) [74]. Five aggregation-prone regions are
detected, encompassing residues 19–23, 31–38, 46–51, 71–78, and
84–89 located in the ß3, ß4 ß5, ß9, and ß10 strands, respectively
(Table 1). The interface of the dimer involves 13 residues: D34,
Y36, Q38, K42-P44, L46, E55, Y87, Q89, Y91, Y96, and F98.
According to their IPIs, the second and fifth stretch are located
preferentially at the interface of the complex, with 89% and 83%
of their residues less than 3 A˚ from the interface, respectively
(Table 1, Figure 1E and Figures 5A, 5B). It is important to note
that both stretches map in preformed ß strands.
AL is distinct from other types of amyloidosis in that
hypervariability yields a different set of mutations in each patient.
Ramirez-Alvarado and co-workers have characterized an LC
Figure 4. Aggregation and interaction regions in human SOD1. In panels A, B and C SOD1 aggregation-prone residues at less and more than
3 A˚ from interaction sites are shown in red and green, respectively. Interface residues not included in aggregation-prone regions are shown in dark
blue. Rest of residues are shown in light blue. A) The predicted interaction surface of a SOD1 monomer is used for calculation. B) The interface in the
native dimeric structure of SOD1 is used for calculation (PDB ID:2C9V). C) Native dimer of SOD1, the second monomer is shown in yellow. D) Ribbon
representation of the SOD1 dimer, predicted aggregation-prone regions are shown in red.
doi:10.1371/journal.pcbi.1000476.g004
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dimer isolated from an AL patient [74]. The pathogenic protein
differs from its germline in seven residues. Only three changes are
non-conservative, and all of them are located at the dimer
interface: N34I, K42Q, and Y87H. The N34I and Y87H
mutations occur precisely in the second and fifth aggregation
prone regions in the protein. Ramirez-Alvarado and co-workers
found that the mutant dimer has an interface that is rotated 90u
from the canonical LC interface. The altered interface was
accompanied by decreased thermodynamic stability of the dimer
and accelerated fibril formation. This might result from the
exposure and self-assembly of the above preformed aggregation-
prone ß segments upon dimer destabilization or dissociation.
Interestingly, the restorative mutation H87Y suffices to regain
thermodynamic stability, delay amyloid formation, and restore the
canonical dimer interface, illustrating a delicate balance between
native and aberrant protein self-assembly.
Although AL is more frequent, in some systemic amyloidosis the
amyloid deposits consist of an unusual form of IgG1 heavy chain
(HC) [75]. The amyloid protein contains the complete heavy-
chain variable (VH) domain contiguous to the third constant
region (CH3) due to the total absence of the first (CH1) hinge and
second (CH2) heavy-chain constant regions [75].
Using the structure of a complete human IgG1 antibody [76] as
a model (PDB ID: 1HZH), we detected nine aggregation-prone
regions in the heavy chain (Table 1). Four of the aggregation-
prone regions are in the VH domain (29–38, 45–52, 87–93, and
100–106), three in the CH2 domain (275–281, 289–299, and 322–
331), and two in the CH3 domain (390–397 and 435–442).
Analysis of the structure of the oligomeric form of the antibody
reveals that only the regions in the VH and CH3 domains of the
heavy chain display high IPI values and therefore are adjacent to
the interface in the native heterotetramer (Table 1, Figure 1C and
Figures 5C, 5D). The truncated, pathogenic form of the IgG is
found in monomeric form in urine, indicating that either it cannot
associate or it dissociates from the light and heavy chains that
block the exposure of the detected aggregating regions in a normal
heterotetrameric IgG molecule. These sequence stretches are
located in preformed ß strands and are ready for self-assembly
reactions that might result in the observed amyloid deposits.
Protein Binding Prevents Aggregation: Human Lysozyme
and Aß42
Human lysozyme forms amyloid fibrils in individuals suffering
from nonneuropathic systemic amyloidosis. The disease is always
Figure 5. Aggregation and interaction regions in human immunoglobulins. In all panels, immunoglobulin (Ig) aggregation-prone residues at less
andmore than 3 A˚ from interaction sites are shown in red and green, respectively. Interface residues not included in aggregation-prone regions are shown
in dark blue. Rest of residues are shown in light blue. A) The interface in the native structure of Ig light chain variable domain (LC) is used for calculation (PDB
ID: 2Q20). B) Native homodimer of Ig LC, the second monomer is shown in yellow. C) The interface in the native structure of IgG heterotetramer is used for
calculation and the Ig heavy chain (HC) represented (PDB ID: 1HZH). D) Native IgG heterotetramer. Ig LCs and the second Ig HC are indicated.
doi:10.1371/journal.pcbi.1000476.g005
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associated with non-conservative point mutations in the lysozyme
gene [77]. Four aggregation-prone regions were detected in
human lysozyme, corresponding to residues 25–33, 57–66, 76–84,
and 108–114. The first region maps in helix B, the second and
third in the loop of the b-domain, and the last one around the
short helix D (Table 1). In good agreement with the predictions,
recent experimental data shows that the region comprising
residues 26–123 is preferentially protected from proteolysis once
it is incorporated into lysozyme amyloid fibrils [78].
Two different interaction clusters are predicted for human
lysozyme (Figure 6A), one in the a-domain and the other in the ß-
domain. The first involves residues in the loop of the b-domain:
N60, R62-W64, N66, A73-N75, A76, and H78. The second
cluster is located in helix C and around helix D and corresponds to
residues A94, K97, R98, R107-W109, and W112. Residues K33
and W34 in helix B are also predicted to be involved in protein-
protein interactions. Overall, 66% of the residues in regions with
high aggregation propensity are less than 3 A˚ from predicted
interaction sites, and 31% overlap with them. Residues 33, 60, 62–
64, 66, 76, 78, 108, 109, and 112 might be implicated in both
binding and aggregation reactions. Interestingly, residues I56, F57,
W64, and D67, which are mutated in the four known single-
residue familial variants associated with lysozyme amyloidosis, are
comprised of or very close to protein segments with high
aggregation propensity and/or interaction sites.
The mechanism of lysozyme aggregation under physiological
conditions probably involves thermal fluctuations that transiently
expose amyloidogenic regions [22]. These transitions are rare in
the wild type protein, but they are more frequent in mutated forms
related to amyloidosis. It has been suggested that residues 36–102
in the b-domain and helix C can unfold while the rest of the a-
domain maintains a native-like conformation [9]. In particular,
residues 78–80 have been proposed to have a high aggregation
propensity and the lowest structural protection, and therefore the
highest propensity to initiate aggregation [79]. This sequence
includes predicted interacting residues in the loop of the ß-domain
and also overlaps with the predicted 76–84 amyloidogenic region.
A single-domain fragment of a camelid antibody has been
shown to inhibit the in vitro aggregation of the D67H amyloido-
genic lysozyme variant [80]. The antibody epitope includes
neither the site of mutation nor most of the protein region
destabilized by the mutation; therefore it was suggested that the
binding of the antibody prevents aggregation by restoring the
structural cooperativity of the mutant protein through the
transmission of long-range conformational effects [80]. The
structure of the antibody-lysozyme complex (PDB ID: 1OP9)
reveals that the epitope consists of 14 residues of the lysozyme
molecule and encompasses residues located in the loop between
the A and B helices in the a-domain (L15, G16, Y20), in the long
loop within the ß-domain (A76, C77, H78, L79), and in the C-
helix (A90, D91, A94, C95, K97, R98, R101) (Figure 6B). The
epitope includes interaction residues in the first and second
predicted clusters. Also, the residues in the loop of the ß-domain
coincide with the 76–84 aggregation-prone region. Therefore, an
Figure 6. New interfaces at human lysozyme and Aß peptide aggregation-prone regions. In all panels, aggregation-prone residues at less
and more than 3 A˚ from interaction sites are shown in red and green, respectively. Interface residues not included in aggregation-prone regions are
shown in dark blue. Rest of residues are shown in light blue. A) The predicted interaction surface of lysozyme is used for calculation. B) The interface
between lysozyme and a camelid antibody is used for calculation (PDB ID: 1OP9). C) Lysozyme complex with a camelid antibody. D) Ribbon
representation of Aß peptide. The interface between the peptide and a designed affibody is used for calculation (PDB ID: 2OTK). E) Aß peptide bound
to a designed affibody.
doi:10.1371/journal.pcbi.1000476.g006
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alternative explanation for the protective action of the antibody
could be that by docking on top of interaction clusters, it impedes
the conformational fluctuation and exposure of the amyloidogenic
region around residues 70–80 (Figure 6C).
A nice example illustrating how new binding interfaces can
effectively inhibit amyloid formation has been recently reported
for the Alzheimer’s Ab peptide. Two aggregation-prone regions
comprising residues 16–21 and 29–40 are consistently predicted
for Ab (Figure 6D). The prediction is in excellent agreement with
the experimental data in the literature indicating that these regions
constitute the core of the Ab fibrils [81]. Ha¨rd and co-workers
have used the Z domain derived from staphylococcal protein A to
evolve variants of this domain able to bind to Ab with nanomolar
affinity and abolish its aggregation (affibodies) [82]. The solution
structure of one of these complexes illustrates how the affibody’s
protective effect is exerted by creating a new, continuous interface
with Ab that buries its two aggregation-prone regions within a
large hydrophobic tunnel-like cavity (Figure 6E).
Non-Amyloidogenic Monomeric Proteins
An important question to address is whether predicted
interaction interfaces and aggregation-prone regions also coincide
in monomeric and soluble proteins. Therefore, we have analyzed
the predicted properties of four well-characterized soluble
proteins: myoglobin, maltose binding protein, thioredoxin, and
ubiquitin.
Human myoglobin is a compact protein not related to disease.
Although after long exposure to high temperatures in vitro it
unfolds and assembles into amyloid fibrils [15], it is a highly
soluble protein in its native a-helical conformation. It displays four
regions with high aggregation potential encompassing residues 8–
15, 28–33, 67–76, and 110–117. This last segment partially
overlaps with the peptide fragment 100–114 found to form
amyloid structures in vitro [83]. A 12-residue interface is
consistently predicted for myoglobin. It consists of residues L40,
K42, F43, L89, S92, I99, P100, K102, Y103, I107, L137, and
F138. Interestingly enough, only one residue (I111) in the
predicted aggregating regions is close to the interface. In addition,
its side chain is buried, resulting in a surface where predicted
interaction and aggregation regions do not overlap (Figure 7A), a
feature that might have evolved to resist aggregation.
Maltose binding protein (MBP) endows fused proteins with
increased solubility indicating that it is by itself highly soluble [84].
However, because it is a relatively large protein (370 residues), 10
different aggregation prone regions are predicted, comprising a
total of 82 residues. Similarly to the case of myoglobin, although 8
of these residues are close to the predicted interface, comprising
residues F92, E153, F156, M321, E322, A324-I329 and W340,
their side chains are not significantly exposed to solvent
(Figure 7B).
Thioredoxin A (TRX) is another tag used to increase the
solubility of recombinant proteins [85]. Three aggregation-prone
regions comprising residues 22–27, 29–33, and 49–57 are detected
in human TRX. The predicted interaction surface comprises
residues T30-I38, D60, V71-T74, and A92. While the first and
third aggregation stretches are at more than 3 A˚ of the predicted
interface, the second one overlaps with it. Surprisingly, in contrast
to myoglobin and MPB, this region is exposed to solvent
(Figure 7C). This suggests that, as discussed in the previous
section, it could be involved in protein assembly reactions. In fact,
residues C32–C35 in this stretch constitute the consensus CXXC
motif in the TRX active site. In agreement with this hypothesis, we
found that in the solution structure of human TRX in a mixed
disulfide intermediate complex with its target peptide from the
transcription factor NF k-B, the second aggregation-prone region
in TRX is part of the complex interface [86] (Figure 7D).
The question arises of why TRX does not self-assemble when it
is free. It appears that evolution uses negative design to fight
against protein deposition by placing amino acids that counteract
aggregation at the flanks of protein sequences with high
aggregation propensity [45]. These residues are called aggregation
gatekeepers [87], and they reduce self-assembly using the repulsive
effect of charge (Arg, Lys, Asp and Glu), the entropic penalty on
aggregate formation (Arg and Lys), or incompatibility with ß-
structure backbone conformation (Pro) [88]. Interestingly, P34 is
adjacent in sequence to the TRX 29–33 aggregation prone region.
P34 and the two basic, protruding K37 and K39 residues flank this
region in the 3D-structure (Figure 7C), which overall would make
self-assembly reactions far more difficult.
Ubiquitin is a small, soluble and highly conserved regulatory
protein that is ubiquitously expressed in eukaryotes [89]. Three
aggregation-prone regions are detected in ubiquitin, including
residues 1–8, 42–47, and 67–74 in the ß1, ß3, and ß5 strands,
respectively. In this case, the regions of the protein with the highest
aggregation propensity overlap significantly with the predicted
interaction interface (Figure 7E). This suggests that in principle,
this surface is competent for protein assembly reactions.
Importantly, it has been shown that ubiquitin binding motifs,
such as CUE domains, bind precisely to a surface defined by the
ß1, ß3, ß4, and ß5 strands of ubiquitin (Figure 7F) [90], illustrating
again how aggregation-prone regions and interaction interfaces
tend to overlap. In fact, biochemical and genetic analyses have
defined the hydrophobic patch formed by the side chains of L8,
I44, and V70 on the surface of ubiquitin as a key determinant for
endocytosis and proteosomal degradation [91]. These three
residues are located in each of the three aggregation-prone regions
predicted for ubiquitin. Why, then, does ubiquitin not self-
assemble when it is unbound in solution? An examination of the
surface defined by the above ß-strands shows that ubiquitin uses
negative design principles to avoid aggregation, placing a large
number of positively charged residues on the edge of these strands
and adjacent to them (Figure 7E). Upon binding to ubiquitin-
binding domains, these basic residues are hidden at the complex
interface.
Non-Amyloidogenic Dimeric Proteins
It seems that the spatial coincidence of interfaces and sequences
promoting self-assembly is not restricted to amyloidogenic
proteins. To further confirm this extent, we analyzed the structure
of 25 different eukaryotic proteins shown to form homodimers
(Table 2 and Figure 8). As expected, the number of predicted
aggregation-prone regions in a protein correlates with its size
(R = 0.88). All the analyzed proteins present at least one
aggregation segment in which half of the residues are closer than
3 A˚ to the interface, and 96% of them have at least one
aggregation region in which .85% of the residues are adjacent to
the interface (Table 2 and Figure 8). This supports the idea that
the physico-chemical determinants of aggregation and native self-
assembly might overlap significantly and is consistent with the
observation that in homodimers, identical monomer subunits tend
to associate by hydrophobic interactions [92]. After protein
synthesis and folding, monomers probably associate rapidly into
native homodimers due to the high local concentration of identical
polypeptide chains, thus avoiding prolonged exposure of hydro-
phobic, aggregation-prone regions to solvent. Interestingly, in
heterodimers, in which monomers spend a larger part of their
lifetime in a non-associated state, the presence of gatekeeper
amino acids (Lys, Arg, Glu, Asp, and Pro) at the complex interface
Globular Proteins Aggregation
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Figure 7. Aggregation and interaction regions in monomeric soluble proteins. In panels A–D, aggregation-prone residues at less and more
than 3 A˚ from interaction sites are shown in red and green, respectively. Interface residues not included in aggregation-prone regions are shown in
dark blue. Rest of residues are shown in light blue. In all panels the predicted interaction surface is used for calculation. A) Human myoglobin (PDB ID:
4MBN). B) Maltose Binding Protein (MBP) (PDB ID: 4MBP). C) Human thioredoxin (TRX) (PDB ID: 3TRX). Gatekeeper residues are shown in purple and
active cysteines in yellow. D) Same orientation that in C, Human TRX in a mixed disulfide intermediate complex with a peptide from the transcription
factor NF kappa B (PDB ID: 1MDI). E) Ribbon representation of human ubiquitin (PDB ID: 1UBQ). Aggregation-prone secondary structures near the
interface are shown in red. Basic residues in the vicinity of aggregation-prone regions are shown in purple. F) Same orientation than E). Complex of
human ubiquitin with a CUE ubiquitin binding domain (PDB ID: 1OTR).
doi:10.1371/journal.pcbi.1000476.g007
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is much greater than in homodimers [92], probably to prevent self-
association between identical monomers.
During the revision of the present work, Vendruscolo and co-
workers published a related study in which they used their
algorithm Zyggregator to perform an extensive analysis of
interfaces in protein-protein complexes [93]. Interestingly enough,
they independently concluded that interface regions are more
prone to aggregate than other surface regions. Also, in excellent
agreement with our analysis on monomeric soluble proteins, they
found that charged residues frequently disrupt hydrophobic
patterns at interfaces and that regions of negative aggregation
propensity tend to surround aggregation-prone regions, which
suggests that monomeric and native oligomeric proteins have
evolved similar strategies to prevent misassembly. In our study, the
analyzed eukaryotic proteins were randomly selected from a
dataset of non-redundant homodimers [92], without any previous
knowledge of their 3D-structures. Interestingly enough, the
aggregation-prone sequences near to the dimer interface are
located in a-helices in ,70% of the cases (Figure 8). This is in
clear contrast with their location in globular amyloidogenic
polypeptides, where they reside mainly in preformed ß-strands.
Although the sample is not statistically significant, this observation
might suggest that natural selection is acting against the presence
of amyloidogenic ß-strands at homodimers interfaces. It is
attractive to propose that, as shown here for amyloidogenic
proteins, mutations at these protein interfaces and specifically at
protective locations might lead to loss of function or toxic
phenotypes in a significant number of, yet undescribed, human
polypeptides.
Conclusions
In the present work, we have used computational tools to
predict aggregation-prone regions and interaction sites in globular
proteins related to depositional diseases and non-pathogenic
Table 2. Overlapping of aggregation-prone regions and interfaces in non-amyloidogenic eukaryotic homodimers.
PDB Protein Source Length
Aggregation
segments
Aggregation
segments close
to the interfase (.50%)1
Aggregation
segments close
to the interfase (.85%)2
1F17 Dehydrogenase Homo sapiens 293 9 2 2
1DQT Antigen Mus musculus 117 8 4 3
1LR5 Auxin binding protein Zea mays 160 7 4 1
1KSO Calcium-binding protein A3 Homo sapiens 93 3 2 2
1EAJ Coxsackie virus Homo sapiens 124 4 2 1
1PE0 DJ-1 Homo sapiens 187 7 1 1
1JR8 Erv2 protein mitochondrial Saccharomyces
cerevisiae
105 5 2 2
1F4Q Grancalcin Homo sapiens 161 6 3 1
1DQP Guanidine phosphoribosyltransferase Giardia lamblia 230 10 3 2
3SDH Hemoglobin Scapharca
inaequivalvis
145 5 2 2
2HHM Hydrolase Homo sapiens 272 11 4 3
8PRK Inorganic pyrophosphatase Saccharomyces
cerevisiae
282 8 3 2
1QMJ Lectin Gallus gallus 132 5 1 1
1M6P Phosphate receptor Bos taurus 146 5 2 1
1MNA Polyketide synthase Streptomyces
venezuelae
276 10 2 1
1F89 Protein YLC351C Saccharomy
cerevisiae
271 11 3 2
1LHP Pyridoxal kinase Ovis aries 306 10 3 1
1QR2 Quinone reductase type 2 Homo sapiens 230 9 5 1
3LYN Sperm lysine Haliotis fulgens 122 6 3 1
1SCF Stem cell factor Homo sapiens 116 4 1 0
1HQO URE2 protein Saccharomyces
cerevisiae
221 8 3 3
1HSS Alpha-amylase inhibitor Triticum aestivum 111 3 2 2
1KIY Trichodiene synthase Fusarium
sporotrichioides
354 12 4 4
1MI3 Xylose reductase Candida tenuis 319 6 1 1
1LBQ Ferrochelatase Saccharomyces
cerevisiae
356 12 3 2
1More than 50% of the residues in the aggregation-prone region are at less than 3 A˚ from a residue located at the interface of the complex.
2More than 85% of the residues in the aggregation-prone region are at less than 3 A˚ from a residue located at the interface of the complex.
doi:10.1371/journal.pcbi.1000476.t002
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polypeptides. From the comparison of the predictions with the
structural and experimental data, it appears that protein-protein
interaction surfaces and regions with high aggregation propensity
overlap significantly in the quaternary structure of proteins.
The proximity and coincidence of protein-protein interfaces
and aggregation-prone regions suggests that the formation of
native complexes and the aggregation of their monomeric subunits
probably compete in the cell. This implies that the molecular
machinery that performs the vast array of cellular functions and
the aggregates that might interfere with these functions promoting
cell stress or even cell death are sustained by similar molecular
contacts. It is likely that the specificity of native protein interfaces
in protein complexes has evolved to minimize anomalous
interactions and therefore detrimental protein aggregation reac-
tions. In this sense, Vendruscolo and co-workers have recently
identified disulfide bonds and salt bridges as specific interactions
that can stabilize aggregation-prone interfaces in their native
conformations in oligomeric proteins [93]. However, the balance
between functional and aberrant self-assembly appears to be so
delicate that point mutations that affect the interface or the
stability of the complex, promoting a higher dissociation rate,
usually lead to the formation of toxic aggregates, either through
direct assembly of newly exposed aggregation-prone regions or by
local unfolding of protein segments previously stabilized in the
native structure of the complex.
Overall, the present analysis provides a rational to understand how
globular proteins aggregate under physiological conditions, where
they posses an initially folded and cooperatively sustained conforma-
tion and extensive denaturation is not expected to occur. The data
strongly suggest that the stabilization of the interface in multimeric
proteins, as in the case of TTR, SOD1, or LC immunoglobulins,
and/or the blocking of conformational fluctuations and exposed
amyloidogenic regions through the formation of new interfaces with
other protein molecules, as in the case of lysozyme or Aß peptide,
might be important strategies to delay the onset or slow the progress
of conformational diseases caused by globular proteins.
The observed association between the failure to attain a native
interface and the build up of harmful aggregates suggests that the
range of genetic human diseases which ultimately might originate
from the conversion of a soluble globular protein into toxic
assemblies could be much larger than previously thought.
Approaches combining the prediction of aggregation-prone
regions from the linear protein sequence with the analysis of real
or predicted protein interfaces in the 3D-structure might provide a
means to identify physiologically and therapeutically relevant
amyloidogenic sequences in the proteins linked to such disorders.
Methods
Prediction of Aggregation-Prone Regions
Aggregation-prone regions in the studied proteins were
predicted using the primary sequence as input and a consensus
of the output of four different available methods. The first
algorithm we used is TANGO (http://tango.crg.es/). TANGO is
based on the physico-chemical principles underlying ß-sheet
formation, extended by the assumption that the core regions of
an aggregate are fully buried [38]. The second algorithm
employed was AGGRESCAN (http://bioinf.uab.es/aggrescan/).
AGGRESCAN is based on the use of an aggregation-propensity
scale for natural amino acids derived from in vivo experiments [40].
The third method, developed by Galzitskaya and co-workers, is
based on the use of a packing density scale for natural amino acids
and on the assumption that amyloidogenic regions are highly
packed in the fibrillar structure [41]. The last approach was
developed by Zhang and co-workers (ftp://mdl.ipc.pku.edu.cn/
pub/software/pre-amyl/). It uses the microcrystal fibrillar struc-
ture of the prion hexapeptide NNQQNY [94] as a template and a
residue-based statistical potential to identify amyloidogenic
fragments of proteins [43]. All analysis was performed using the
default parameters for each employed algorithm. In the present
work, a sequence stretch in the analyzed proteins should comprise
a minimum of five consecutive residues and be positively predicted
Figure 8. Aggregation-prone regions at the interface of selected homodimeric eukaryotic proteins. Aggregation-prone regions in which
more than 85% of the residues are at less than 3 A˚ from the interface are highlighted in green. The PDB ID is indicated for each dimer (see also
Table 2).
doi:10.1371/journal.pcbi.1000476.g008
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by at least two of the above-mentioned methods to be considered
an aggregation-prone region.
Prediction of Protein-Protein Interaction Sites
Interaction residues were predicted using the monomeric three-
dimensional crystal structure of each of the studied proteins as input
and a consensus of the output of three different algorithms. The first
approach used to predict interaction surfaces was the Optimal
Docking Area (ODA) method (http://www.molsoft.com/oda),
which identifies continuous surface patches with optimal docking
desolvation energy based on atomic solvation parameters adjusted
for protein-protein docking [32]. Only the top ten ODA hot spots
were considered. The second method we used was SHARP2
(http://www.bioinformatics.sussex.ac.uk/SHARP2). SHARP2 cal-
culates multiple parameters for overlapping patches of residues on
the surface of a protein. It considers the solvation potential,
hydrophobicity, accessible surface area, residue interface propen-
sity, planarity, and protrusion. Parameter scores for each patch are
combined, and the patch with the highest combined score is
predicted as a potential interaction site [31]. The patch size was
selected by considering the interacting partner to be an identical
protein, and only residues in the best-scoring patch were considered.
The last algorithm used was InterProSurf (http://curie.utmb.edu/).
This method is based on solvent-accessible surface area of residues
in isolated proteins, a propensity scale for interface residues, and a
clustering algorithm to identify surface regions with residues of high
interface propensities [33]. Only the first five clusters were
considered. All analysis was done using the default parameters for
each algorithm. In the present work, a residue in the surface should
be identified as at least by two of the above mentioned approaches
to be considered an interaction site.
Evaluation of Interface Proximity
To evaluate whether the proximity of an aggregation-prone
region to a given real interface is specific or the sequence stretch is
as close to any other patch of the same size in the protein surface,
we have defined the Interface Proximity Index: IPI
IPI = 1-(SP/IP)
IP = Interface Proximity = nR/nHS
SP~Surface Proximity~
X100
nS~1
nS=nHS
,
100
nR = number of residues in the aggregation-prone region at less
than 3 A˚ from the interface.
nHS = number of residues in the aggregation-prone region.
nS = number of residues in the aggregation-prone region at less
than 3 A˚ from a randomly chosen protein surface that does not
include the interface.
Each random surface was generated by an aleatory selection of a
number of solvent exposed residues equal to the number of residues
constituting the real interface. One hundred random surfaces were
generated for each aggregation-prone region analyzed.
Solvent-accessible and buried residues in the monomeric
complex subunits where identified using the PISA server at the
European Bioinformatics Institute (http://www.ebi.ac.uk/msd-srv/
prot_int/pistart.html).
An IPI#0 indicates that the aggregation-prone region is equally
or less close to the interface than to the rest of the surface. An
IPI.0 indicates that the aggregation-prone region is closer to the
interface than to the rest of the surface, e. g., an IPI = 0.5 indicates
that the aggregation-prone region is half as far from the interface
than from the rest of the surface. The maximum value for IPI is 1.
Figures were were generated with the Swiss-PDB viewer
program (http://spdbv.vital-it.ch) and rendered with POV
(Persistance of Vision).
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